🥰

Cause you got that James Dean daydream look in your eye And I got that red lip classic thing that you like And when we go crashing down, we come back every time 'Cause we never go out of style, we never go out of style

Olivia Rodrigo

Im a proud member of the human species

@plainyogurt21 Mendelian randomization studies tend to be a bit more credible when directionally aligned with some human data

ZEUS from $NVO - I think this works. Based Cantos and first principles of hsCRP as a risk factor. TAM for this indication is ~5B so I think NVO can move up ~20B (+10%) with success. Readthrough to $BIOA $GLUE (not $NMRA $AVTX lol) It's hard to replicate the Cantos powering, but let’s keep simple simple -> hsCRP independent risk factor -> we hit hsCRP. Prior Phase 3 PoC. Enriched population, base line case is stat sig high .8s HR. The positives from this trial are the data from the CANTOS group and some of the genetic evidence showing that HSCRP is associated with an increased risk of cardiovascular events. The negatives are: - The novel trial population - Use of SGLT-2, which can reduce the rate of cardiovascular events and death - Use of GLP-1, which drops HSCRP across the population, including kidney disease patients and stage 4 kidney disease patients with a different pathology on cardiovascular events I don't think any of those, except GLP-1 use, changes the effect size of using an HSCRP-reducing agent. I still think the hazard ratio is coming in right around that 0.85 range. For NVO, the catalyst path is quit interesting with hemophilia, Oral wegovy, Etavopivat, FGF21 etc. Side note: I am skeptical on the Novartis LP(a) trial. It’s an iffy readout when we're already managing these patients with aspirin and LDL based therapy. Co administration with aspirin will alleviate ALL the thrombotic risk and some evidence suggests it will attenuate any secondary prevention (for sure helps in primary prevention).

I’ll be right back , don’t fall in the toilet , okay?

My dream job

da bih gah da bih gah

@A_May_MD @Biohazard3737 If it doesn’t sound next gen enough then I don’t want it!

@Biohazard3737 Almost seems like the safe and highly effective standard of care is highly effective. Idk.

I have no idea why people really thought a silencer would work on top of a stabilizer- other than magic thinking. Also, shows you how lucky $ALNY got.

The best way to hedge is to simply make sure you’re up huge profits

almost got a paper cut today

Boo boo bee bee boo boo bee bee

Meow meow mew mew meow meow mew mew meow meow mew mew meow meow mew mew

@A_May_MD You know being an alcoholic is bad for your skin right?

Revenge match. #MillerHighLife #USMNT #ChampagneOFBEERS dailymail.com/news/article-1…

Getting high before deep tissue massage has me drooling.. Oopsie!

@Sanctuary_Bio Fun hasn’t even gotten started

$NVO breaks 50. This has been one of the easiest trades I've put on this year and also incredibly accretive to my P&L. As I've said $ is fungible. doesn't care where it comes from. If you give an opportunity for free $ I'm not saying no even if it is "boring"

I take my whiskey neat My coffee black and my bed at three You're too sweet for me You're too sweet for me Ooh Ooh Ooh Ooh

A few shots

This weather calls for a shot and some pain killers

Wow I’m coming up in this world new record 🚀

@CoalPowers That’s mine

Found someones Nov ‘21 budget on the sidewalk.